What clinical evidence did Drugnews report for OBI-992?
As of Drugnews’s October 30, 2026 Taiwan ADC analysis, OBI Pharma’s TROP2-targeting OBI-992 was in early clinical development, with about 117 planned patients across eight U.S. and Taiwan sites. The trial began on June 12, 2024. The article reports partial responses in three patients by December 2025 and describes four payloads per antibody; these are not pivotal efficacy results.
| Measure | Reported result | Basis |
|---|---|---|
| Planned enrollment | About 117 patients | Study design, not completed enrollment |
| Trial footprint | eight sites | United States and Taiwan |
| Reported partial responses | three patients | Early company-reported observation |
| Drug-to-antibody ratio | four payloads per antibody | Molecular design, not response rate |
The partial-response count has no denominator here and is not an objective response rate or a comparison against another drug.